Os Therapies Incorporated (OSTX) Stock Price, Quote & News

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 297 7793

Website: ostherapies.com

Address:

115 Pullman Crossing Road, Suite 103, Grasonville, United States

TeaBaggerVance Feb. 17 at 12:54 PM

$OSTX This morning’s PR from OS Therapies confirms what longs have been saying — we’re right on schedule. Regulatory filings are progressing exactly as planned, with BLA modules submitted and global applications on track for Q1. Just as important, the overhang from Ayala Pharmaceuticals is now behind us. Their dissolution and liquidation removes uncertainty and potential selling pressure tied to prior disclosures. Execution is happening. Timeline is intact. Headwinds are fading. 🚀

0 · Reply

PrivateWealthPro Feb. 17 at 12:24 PM

$OSTX Pre-revenue biotech; early-stage oncology pipeline.

1 · Reply

Danyao Feb. 17 at 12:19 PM

$OSTX Correction: Ayala didn't just sell 800k. they dumped 3.5M shares on-market. Fintel shows 2.2M common shares to stay under the 9.9% cap, but the other 2.6M were likely $0.01 warrants. No wonder we’ve been bleeding since December.

0 · Reply

MrTicker Feb. 17 at 11:59 AM

$OSTX OS Therapies Targets U.K. MHRA And EMA Conditional MAA Submissions By End Of Q1 2026 For OST-HER2 In Fully Resected Pulmonary Metastatic Osteosarcoma BENZINGA 5:08 AM ET 2/17/2026

0 · Reply

Danyao Feb. 17 at 11:44 AM

$OSTX Turns out the Feb 9 block deal was Ayala! Looks like they dumped 800k shares on the open market and tucked the other 1.3M away with a whale. UK’s lagging a bit due to the extra biomarker, but maybe a massive triple-release on March 31?

0 · Reply

newsfile_corp Feb. 17 at 11:02 AM

https://nfne.ws/284086 $OSTX @ostherapies #Chemicals #Biotechnology #Investing

0 · Reply

LioGod Feb. 17 at 1:52 AM

$OSTX wow did it spike up AH??

0 · Reply

TeaBaggerVance Feb. 17 at 1:50 AM

$OSTX 📈👀

0 · Reply

Bearbull_Baggins Feb. 16 at 1:12 AM

$OSTX New 13F updates show who the 9 investors that bought in at 1.40 recently. That's a decent group 👌 Ingalls & Snyder LLC - 36,676 shares Stifel Financial Corp - 15,000 shares Morgan Stanley - 1,000 shares (womp womp) State Street Corp - 58,500 shares Jane Street Group - 27,740 shares Blackrock, Inc. - 61,425 shares LPL Finanacial - 10,113 shares CM Management - 400,000 shares Geode Capital Management - Increased position by 31% to 246,038 shares

0 · Reply

iholdTNXPbutIhateSeth Feb. 15 at 1:40 PM

$OSTX

0 · Reply

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma

Feb 4, 2026, 12:45 PM EST - 12 days ago

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies

Feb 2, 2026, 6:00 AM EST - 15 days ago

OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 15, 2026, 12:30 PM EST - 4 weeks ago

OS Therapies Bone Cancer Trial Data Strengthens FDA Case

Jan 15, 2026, 7:00 AM EST - 4 weeks ago

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 14, 2026, 7:00 AM EST - 4 weeks ago

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

Jan 12, 2026, 8:01 AM EST - 5 weeks ago

OS Therapies Enters into Warrant Inducement Agreements

Jan 5, 2026, 7:40 AM EST - 6 weeks ago

OS Therapies Provides First Half 2026 Corporate Outlook

Dec 15, 2025, 6:00 AM EST - 2 months ago

OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 9, 2025, 7:40 AM EST - 2 months ago

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 5, 2025, 8:01 AM EST - 2 months ago

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

Nov 25, 2025, 9:21 AM EST - 3 months ago

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

Nov 21, 2025, 4:15 PM EST - 3 months ago

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

Nov 20, 2025, 7:40 AM EST - 3 months ago

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

Nov 17, 2025, 6:00 AM EST - 3 months ago

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 22, 2025, 9:15 AM EDT - 4 months ago

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 17, 2025, 9:15 AM EDT - 4 months ago

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 10, 2025, 6:00 AM EDT - 4 months ago

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

Oct 9, 2025, 7:40 AM EDT - 4 months ago

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Oct 7, 2025, 11:50 AM EDT - 4 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events

Sep 30, 2025, 7:40 AM EDT - 5 months ago

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

Sep 19, 2025, 7:40 AM EDT - 5 months ago

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

Sep 12, 2025, 7:40 AM EDT - 5 months ago

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Sep 8, 2025, 5:12 PM EDT - 5 months ago

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Sep 3, 2025, 7:40 AM EDT - 5 months ago

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

Sep 2, 2025, 7:40 AM EDT - 6 months ago

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Sep 2, 2025, 6:00 AM EDT - 6 months ago

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

Aug 27, 2025, 4:01 PM EDT - 6 months ago

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

Aug 25, 2025, 9:51 PM EDT - 6 months ago

OS Therapies Terminates Equity Line of Credit

Aug 19, 2025, 6:00 AM EDT - 6 months ago

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 5:44 PM EDT - 6 months ago

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

Aug 7, 2025, 9:00 AM EDT - 6 months ago

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Aug 7, 2025, 6:00 AM EDT - 6 months ago

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jul 14, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Jul 10, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Provides Clinical & Global Regulatory Updates

Jul 3, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jun 30, 2025, 6:00 AM EDT - 8 months ago

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

Jun 24, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 23, 2025, 8:29 PM EDT - 8 months ago

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

Jun 10, 2025, 7:40 AM EDT - 9 months ago

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 6, 2025, 7:30 AM EDT - 9 months ago

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

May 16, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 7, 2025, 8:45 AM EDT - 10 months ago

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

May 2, 2025, 9:32 AM EDT - 10 months ago

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Apr 22, 2025, 7:40 AM EDT - 10 months ago

OS Therapies FDA Meeting Request Granted

Apr 10, 2025, 7:42 AM EDT - 11 months ago

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

Apr 9, 2025, 7:40 AM EDT - 11 months ago

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

Apr 7, 2025, 6:00 AM EDT - 11 months ago

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

TeaBaggerVance Feb. 17 at 12:54 PM

0 · Reply

PrivateWealthPro Feb. 17 at 12:24 PM

$OSTX Pre-revenue biotech; early-stage oncology pipeline.

1 · Reply

Danyao Feb. 17 at 12:19 PM

0 · Reply

MrTicker Feb. 17 at 11:59 AM

$OSTX OS Therapies Targets U.K. MHRA And EMA Conditional MAA Submissions By End Of Q1 2026 For OST-HER2 In Fully Resected Pulmonary Metastatic Osteosarcoma BENZINGA 5:08 AM ET 2/17/2026

0 · Reply

Danyao Feb. 17 at 11:44 AM

0 · Reply

newsfile_corp Feb. 17 at 11:02 AM

https://nfne.ws/284086 $OSTX @ostherapies #Chemicals #Biotechnology #Investing

0 · Reply

LioGod Feb. 17 at 1:52 AM

$OSTX wow did it spike up AH??

0 · Reply

TeaBaggerVance Feb. 17 at 1:50 AM

$OSTX 📈👀

0 · Reply

Bearbull_Baggins Feb. 16 at 1:12 AM

0 · Reply

iholdTNXPbutIhateSeth Feb. 15 at 1:40 PM

$OSTX

0 · Reply

iholdTNXPbutIhateSeth Feb. 14 at 10:17 PM

$OSTX

0 · Reply

TeaBaggerVance Feb. 13 at 9:15 PM

$OSTX New 8-K just released. Looks like they extended the warrant inducement deadline from 2/10 to March 2nd. The stock price wasn’t above the $1.40 mark long enough for the all the holders to cash in. They should be very motivated to get the stock price well above that $1.40 mark in the next couple of weeks to close this inducement out. I see news coming very soon to give this a jolt. ⚡️

0 · Reply

cwork Feb. 13 at 8:14 PM

$OSTX New podcast 🎙️ CEO Paul Romness joins Cell & Gene: The Podcast to share how OS Therapies is tackling pulmonary metastatic osteosarcoma with a HER2-targeted immunotherapy approach and insights from a recent Phase 2B trial. Listen here with a free subscription or on your favorite podcast platform: https://bit.ly/4csuM0i $OSTX

0 · Reply

iholdTNXPbutIhateSeth Feb. 13 at 8:02 PM

$OSTX 4 hr MACD crossing back up

0 · Reply

Bearbull_Baggins Feb. 13 at 7:40 PM

$OSTX 4 hr MACD crossing back up finally. Nice to see before a long weekend. We'll be fine down here

0 · Reply

iholdTNXPbutIhateSeth Feb. 13 at 4:31 PM

$OSTX

0 · Reply

Indycolts2004 Feb. 13 at 4:20 PM

$OSTX Nice and steady

0 · Reply

ACstranger Feb. 13 at 8:25 AM

$OSTX very

0 · Reply

God5000 Feb. 13 at 1:45 AM

$OSTX one more institution got in today, total 34

3 · Reply

iholdTNXPbutIhateSeth Feb. 12 at 10:41 PM

$OSTX

0 · Reply

TeaBaggerVance Feb. 12 at 10:37 PM

$OSTX We’re all excited about getting the BLA accepted and leading towards the PRV in September, but we have a lot of other meaningful news in the pipeline that could be released very soon. Here are a couple clips from the 2026 Corporate Outlook they released in early January.

1 · Reply

iholdTNXPbutIhateSeth Feb. 12 at 7:27 PM

$OSTX 😭😭

0 · Reply

Market Cap	42.96M
Revenue (ttm)	0.00
Net Income (ttm)	-8.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	218,400
Avg Vol	608,936
Day's Range	N/A - N/A
Shares Out	35.21M
Stochastic %K	21%
Beta	-3.79
Analysts	Strong Sell
Price Target	$12.75